AKI Alerts for Acute Kidney Injury
Trial Summary
What is the purpose of this trial?
The primary objective of this study is to determine whether the use of uplift (also known as Conditional Average Treatment Effect - CATE) modeling to empirically identify patients expected to benefit the most from AKI alerting and to target AKI alerts to these patients will reduce the rates of AKI progression, dialysis, and mortality.
Do I have to stop taking my current medications for the AKI Alerts trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that AKI Alerts for Acute Kidney Injury is an effective treatment?
The available research shows mixed results about the effectiveness of AKI Alerts for Acute Kidney Injury. Some studies suggest that these alerts can help in recognizing the condition early, which is crucial for better outcomes. However, other studies, like the one conducted at Brandenburg Medical School, found that the alerts did not significantly improve important outcomes like reducing the need for dialysis or lowering in-hospital death rates. This suggests that while AKI Alerts might help in early detection, they may not always lead to better treatment results unless they are well-integrated with a clinical response plan.12345
What safety data exists for AKI alert systems?
The safety data for AKI alert systems, also known as electronic alerts for acute kidney injury, is primarily focused on their impact on patient outcomes, recognition, and management of AKI. While these systems have been implemented in various electronic health records worldwide, the evidence of their benefit on outcomes remains uncertain. Studies have shown feasibility and some changes in AKI demographics and outcomes following their implementation, but major randomized trials have yet to conclusively demonstrate significant improvements in patient safety or outcomes.14678
Research Team
Francis Wilson, MD
Principal Investigator
Yale University
Eligibility Criteria
This trial is for adults over 18 who are hospitalized and have acute kidney injury (AKI) as shown by a significant rise in creatinine levels. It's not open to those already on dialysis, with very high initial creatinine, previous participation, hospice care, recent kidney transplant or opted out of health record research.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Intervention
Participants are randomized into 'recommended' or 'anti-recommended' groups based on uplift scores, and alerts are generated accordingly
Follow-up
Participants are monitored for AKI progression, dialysis, or mortality
Extended Follow-up
Participants are monitored for secondary outcomes such as AKI best practices and readmission rates
Treatment Details
Interventions
- Alert
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator